MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RLYB had $17,471K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$17,471K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Proceeds from sale of common sto...
    • Loss on investment in joint vent...
    • Others
Negative Cash Flow Breakdown
    • Gain on sale of joint venture
    • Purchases of marketable securiti...
    • Prepaid expenses, operating righ...
    • Others

Cash Flow
2025-12-31
Net loss
-8,978
Depreciation and amortization
92
Net accretion of discounts/premiums on debt securities
-573
Share-based compensation
5,314
Gain on sale of joint venture
22,350
Loss on investment in joint venture
-874
Prepaid expenses, operating right-of-use assets and other current assets
2,043
Accounts payable
-152
Accrued expenses and operating lease liabilities
-1,149
Deferred revenue
-848
Net cash used in operating activities
-29,813
Purchases of marketable securities
17,697
Proceeds from maturities of marketable securities
46,465
Proceeds from sale of common stock received from sale of joint venture
20,000
Investment in joint venture
1,500
Net cash provided by investing activities
47,268
Proceeds from the issuance of common stock from a securities purchase agreement
0
Proceeds from the issuance of common stock under the stock purchase plan
16
Payments of offering costs
0
Net cash provided by financing activities
16
Net increase (decrease) in cash and cash equivalents
17,471
Cash and cash equivalentsbeginning of year
13,903
Cash and cash equivalentsend of year
31,374
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$46,465K Proceeds from sale ofcommon stock received...$20,000K Proceeds from theissuance of common stock...$16K Net cash provided byinvesting activities$47,268K Net cash provided byfinancing activities$16K Canceled cashflow$19,197K Net increase(decrease) in cash and cash...$17,471K Canceled cashflow$29,813K Purchases of marketablesecurities$17,697K Investment in joint venture$1,500K Share-based compensation$5,314K Loss on investment injoint venture-$874K Depreciation andamortization$92K Net cash used inoperating activities-$29,813K Canceled cashflow$6,280K Gain on sale of jointventure$22,350K Net loss-$8,978K Prepaid expenses,operating right-of-use...$2,043K Accrued expenses andoperating lease...-$1,149K Deferred revenue-$848K Net accretion ofdiscounts/premiums on debt...-$573K Accounts payable-$152K

Rallybio Corp (RLYB)

Rallybio Corp (RLYB)